Skip to main content
OpenTrials
Completed

NCT Number: NCT04693403

The Acute Respiratory Intervention StudiEs in Africa (ARISE-AFRICA) Study

The dearth of Intensive care units in low resource settings portends for poor outcomes amongst patients with acute hypoxemic respiratory failure (AHRF) . To our knowledge, the effect of CPAP and HFNC on major outcomes has not been assessed in adults with AHRF in resource-limited settings. The aim of this prospective, multicenter, randomized, controlled, trial is to determine whether High-flow oxygen through a nasal cannula (HFNC) or Continuous positive airway pressure (CPAP) system can reduce mortality among patients with acute hypoxemic respiratory failure (AHRF) in a limited resource setting as compared with standard low flow oxygen therapy?

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–95 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Entebbe Regional Referral Hospital, Entebbe, Uganda

Loading trial locations.

About this study

The care for the critically ill patient typically takes place in the intensive care unit (ICU). ICU care is quite expensive, even in resource rich countries. The most common reason for ICU admission globally is respiratory support for acute hypoxemic respiratory failure (AHRF). In patients with AHRF, the need for invasive mechanical ventilation is associated with high mortality, especially in low income countries (LICs), given the scarce availability of invasive mechanical ventilation. Some studies suggest that administration of ventilatory support through a mask may be effective in resource-limited settings. However, there is no clinical study data in adults to support this evidence. Human and material constraints are major barriers for the care of critically-ill patients in resource limited settings , advocating the need for a frugal approach. Furthermore, the scarcity of intensive care unit care in LICs contributes to a high mortality among acutely ill patients. The current corona virus pandemic has further highlighted the need for frugal acute care interventions in LICs.

Continuous positive airway pressure (CPAP) is a simple to use and affordable technique for noninvasive ventilatory support. High-flow oxygen through a nasal cannula (HFNC) may also offer an alternative in patients with hypoxemia. The high flow rates may also decrease physiological dead space by flushing expired carbon dioxide from the upper airway, a process that potentially explains the observed decrease in the work of breathing.

Frugal CPAP or HFNC , as compared with standard oxygen therapy, could reduce the mortality among adults presenting with AHRF in a resource-limited setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • De novo acute respiratory distress, as defined by dyspnea, use of accessory respiratory muscles, and a respiratory rate of 25 breaths per minute or more,
  • Hypoxemia, as defined by a ratio of the partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) of less than 300 mm Hg or a oxygen saturation by pulse oximetry SpO2/FiO2 ratio <315 will be considered for inclusion
  • Informed consent obtained in accordance with local regulations;

Exclusion criteria

  • Exacerbation of asthma, chronic obstructive pulmonary disease or another known or suspected chronic respiratory disease;
  • Absolute contraindications to CPAP or HFNC
  • Cardiac arrest; severe ventricular arrhythmia; shock defined by the need for vasopressors (dopamine > 5 microg/kg/min or adrenaline or noradrenaline at any dose)
  • Altered consciousness (Coma Glasgow Score below 12 points);
  • Do not intubate order, do not resuscitate order, or decision to limit full care taken before obtaining informed consent;
  • Refusal to participate, prior enrolment in the trial, participation in another interventional study on respiratory distress;

Treatment and study plan

HFNC

Procedure

40-60l/min humidified oxygen by nasal cannula

Other names: High-flow oxygen by nasal cannula

cPAP

Procedure

Oxygen therapy by boussignac Continuous positive airway pressure face mask

Other names: Continuous positive airway pressure

standard oxygen

Procedure

Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask

Other names: Standard Oxygen Therapy (low flow)

Primary outcomes

  1. Mortality

    Time frame: 28 day

    Number of study participants deceased at day 28 of study randomisation

Secondary outcomes

  1. Number of patients intubated and ventilator-free

    Time frame: 28 days

    Number of patients intubated and ventilator-free at 28 days from randomisation

  2. Patient Tolerance to CPAP or HFNC

    Time frame: 7 days

    Patients will be assessed using the Likert scale

  3. Organ failure free days

    Time frame: 7 days

    Number of days from randomisation free of organ failure

  4. Number of patients who meet criteria for intubation at day 7

    Time frame: 7 days

    Number of patients who meet criteria for intubation at day 7 of randomisation

Sponsors and collaborators

Lead sponsor

Makerere University

Other

Collaborators

  • Paris 12 Val de Marne University
  • THRiVE
  • Wellcome Trust

Registry information

Official study title

A Multicentre, Randomized, Clinical Trial of Respiratory Support With Standard Low Flow Oxygen Therapy, Continuous Positive Airway Pressure, and High-flow Oxygen Therapy in Adults With Acute Hypoxemic Respiratory Failure in Uganda

Acronym: ARISE-AFRICA

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jan 5, 2021
Registry last updated
Aug 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.